DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for inappropriate ADH syndrome — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleInappropriate ADH syndrome maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
approvedTolvaptanApproved drug
Structures already discussed alongside inappropriate adh syndrome in the retrieved literature, rendered from public PubChem SMILES. Which drugs appear here reflects the evidence found, not a ranked prediction.
Molecular view
arginine vasopressin receptor 2 (AVPR2) — AVPR2 is one of the genes in this disease's Open Targets module — part of the target space DeCure's repurposing candidates point at. The protein backbone is drawn as a cartoon. The structure has cholesterol bound in it, shown as sticks.
Loading structure…
helix sheet clrdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7DW9 · 2.6 Å · ligand CHOLESTEROL (CLR). Experimental structure, not a prediction.
What the evidence adds up to
The 2019 audit from a UK district general hospital describes SIADH as a condition of increased ADH secretion leading to water retention and low plasma sodium (hyponatraemia). The audit states that management includes stopping the causative drug, fluid restriction, and using medications such as Tolvaptan and Demeclocycline. The audit itself was an attempt to check whether prevailing guidelines were followed in that hospital; it does not report any patient outcomes, response rates, or survival data. No numbers of patients audited are given, and no results of the audit are presented in the abstract.
A 1968 letter to the editor discusses the possibility of inappropriate ADH release as a contributing factor in certain paediatric cases, but the authors note they had difficulty explaining why it would arise and therefore had not originally mentioned it. They raise a hypothetical possibility of a latent renal defect becoming apparent under water-loading stress. No drug treatments, patient numbers, or outcomes are reported in this letter.
The three abstracts provide no clinical trial data, no comparative effectiveness results, and no evidence that any drug repurposing has been tested for SIADH. The only drugs named (Tolvaptan and Demeclocycline) are mentioned as existing management options, not as repurposed agents. No concrete survival or response rates are given for any intervention.
What is missing: prospective trials comparing standard care (fluid restriction, stopping culprit drugs) against any repurposed drug; any data on patient stratification by aetiology of SIADH; funding for a controlled study that reports sodium correction rates, adverse events, and length of hospital stay. The audit format described cannot provide evidence of efficacy, and the 1968 letter offers only speculation.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
GSC Biological and Pharmaceutical Sciences · 2019 · 1 citations · open access
An audit on the management of patients with SIADH (Syndrome of inappropriate ADH secretion) in a District General hospital in the UK
AbstractSyndrome of inappropriate ADH (SIADH) secretion is a condition where there is an increase in the secretion of ADH resulting in retention of excess water in the body. ADH or Antidiuretic hormone (also called Vasopressin) is produced in the hypothalamus of the brain and released by the pituitary gland. The main biochemical abnormality is low plasma sodium or hyponatraemia. However hyponatraemia can occur for multiple reasons and it is important to diagnose the specific cause as the management can vary. SIADH is a cause for euvolaemic hyponatraemia and the management includes stopping the drug responsible for causing it, fluid restriction and using medications like Tolvaptan and Demeclocycline. The audit below is an attempt to find out if the prevailing Guidelines were considered during the management of SIADH in our hospital.
AbstractWe thank Drs. Moore and Edelmann for their detailed comments. Although inappropriate ADH release had occurred to us as a contributing factor, we had difficulty in explaining just why it would have arisen in these cases, and therefore did not mention it. But since, as Drs. Moore and Edelmann point out, inappropriate ADH is not well understood anyhow, perhaps we should not have been so reticent. A hypothetical possibility is the existence in these children of a latent defect in renal function which became apparent only under conditions of stress, namely water-loading.
Zenodo (CERN European Organization for Nuclear Research) · 2019 · 0 citations · open access
An audit on the management of patients with SIADH (Syndrome of inappropriate ADH secretion) in a District General hospital in the UK
AbstractSyndrome of inappropriate ADH (SIADH) secretion is a condition where there is an increase in the secretion of ADH resulting in retention of excess water in the body. ADH or Antidiuretic hormone (also called Vasopressin) is produced in the hypothalamus of the brain and released by the pituitary gland. The main biochemical abnormality is low plasma sodium or hyponatraemia. However hyponatraemia can occur for multiple reasons and it is important to diagnose the specific cause as the management can vary. SIADH is a cause for euvolaemic hyponatraemia and the management includes stopping the drug responsible for causing it, fluid restriction and using medications like Tolvaptan and Demeclocycline. The audit below is an attempt to find out if the prevailing Guidelines were considered during the management of SIADH in our hospital.
Zenodo (CERN European Organization for Nuclear Research) · 2019 · 0 citations · open access
An audit on the management of patients with SIADH (Syndrome of inappropriate ADH secretion) in a District General hospital in the UK
AbstractSyndrome of inappropriate ADH (SIADH) secretion is a condition where there is an increase in the secretion of ADH resulting in retention of excess water in the body. ADH or Antidiuretic hormone (also called Vasopressin) is produced in the hypothalamus of the brain and released by the pituitary gland. The main biochemical abnormality is low plasma sodium or hyponatraemia. However hyponatraemia can occur for multiple reasons and it is important to diagnose the specific cause as the management can vary. SIADH is a cause for euvolaemic hyponatraemia and the management includes stopping the drug responsible for causing it, fluid restriction and using medications like Tolvaptan and Demeclocycline. The audit below is an attempt to find out if the prevailing Guidelines were considered during the management of SIADH in our hospital.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
